Orchestra BioMed Holdings Future Growth
Future criteria checks 2/6
Orchestra BioMed Holdings is forecast to grow earnings and revenue by 5.4% and 42.3% per annum respectively while EPS is expected to grow by 4.6% per annum.
Key information
5.4%
Earnings growth rate
4.6%
EPS growth rate
| Medical Equipment earnings growth | 17.1% |
| Revenue growth rate | 42.3% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 14 Nov 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 4 | -61 | N/A | N/A | 2 |
| 12/31/2025 | 4 | -70 | N/A | -46 | 5 |
| 12/31/2024 | 3 | -61 | N/A | -51 | 5 |
| 9/30/2024 | 3 | -58 | -48 | -48 | N/A |
| 6/30/2024 | 2 | -56 | -45 | -45 | N/A |
| 3/31/2024 | 2 | -52 | -45 | -45 | N/A |
| 12/31/2023 | 3 | -49 | -46 | -46 | N/A |
| 9/30/2023 | 4 | -46 | -44 | -44 | N/A |
| 6/30/2023 | 4 | -43 | -41 | -41 | N/A |
| 3/31/2023 | 4 | -39 | -39 | -38 | N/A |
| 12/31/2022 | 4 | -34 | -30 | -29 | N/A |
| 9/30/2022 | 0 | -32 | -26 | -25 | N/A |
| 6/30/2022 | 0 | -27 | -23 | -23 | N/A |
| 3/31/2022 | -1 | -25 | -19 | -19 | N/A |
| 12/31/2021 | -1 | -23 | -20 | -19 | N/A |
| 12/31/2020 | 6 | -21 | -27 | -26 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OBIO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: OBIO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: OBIO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: OBIO's revenue (42.3% per year) is forecast to grow faster than the US market (9% per year).
High Growth Revenue: OBIO's revenue (42.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OBIO's Return on Equity is forecast to be high in 3 years time